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Abstract
Background: The prevalence of obesity is escalating alarmingly worldwide, and it is now becoming a rapidly
growing epidemic in developing countries. Recent studies have reported that zinc has been implicated in altered
lipid markers, insulin resistance and some obesity markers. There is a lack of evidence on zinc as a potential
therapeutic agent to reduce weight and improve metabolic parameters in obese adults. The present study is
designed to evaluate the effects of zinc supplementation on obese adults in Sri Lanka. Furthermore, we aim to
evaluate the effects of zinc supplementation on metabolic parameters in this population.
Methods/design: This study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a
period of 3 months at the clinical laboratory, Department of Applied Nutrition, Wayamba University of Sri Lanka to
assess the efficacy of daily zinc 20 mg supplementation in obese subjects. There will be a total of 80 subjects, aged
between 18–60 years, of both genders, who are obese (body mass index (BMI) ≥25). Subjects will be stratified
according to age, gender and BMI and randomly assigned into the test and placebo groups in a 1:1 ratio. The
treatment drug is a capsule containing elemental zinc 20 mg as the active ingredient (as zinc sulphate). The placebo
capsule will contain lactose monohydrate. The subjects will receive either zinc capsules or placebo daily for 3 months.
The study treatments will be double blinded to both investigator and subject. The visits and the evaluations will be as
follows: screening (visit 0), baseline (visit 1) and 3 month (visit 2). The primary outcome will be weight reduction
among the obese subjects. Secondary outcome measures include glycaemic status (fasting blood glucose), lipid
parameters (total cholesterol, triglyceride levels, high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol) and blood pressure.
Discussion: The trial protocol will aim to establish the effects of zinc supplementation on weight reduction and
metabolic risk parameters among obese subjects.
Trial registration: Sri Lanka Clinical Trials Registry: SLCTR/2014/020. Registered on 18 September 2014.
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Background
The prevalence of obesity is escalating alarmingly world-
wide, and now it is becoming a rapidly growing epidemic
in developing countries including south Asia [1]. Obesity
is a major public health problem in Sri Lanka [2]. The
level of obesity in Sri Lanka has increased several fold
during last two decades, and nearly a quarter of adults
have a body mass index (BMI) of more than 25 [3]. More
seriously, obesity-associated metabolic problems such as
diabetes (~11 %) [4], hypertension (~20 %) [4] and
metabolic syndrome (~25 %) [5] are also highly prevalent
among Sri Lankan adults. On the other hand, several
micronutrient deficiencies are also still major public
health issues in Sri Lanka, including zinc deficiency [6].
A low plasma zinc level is associated with obesity [7, 8].
Zinc may regulate serum leptin concentration [9] and
appetite control. Zinc (Zn), an essential micronutrient and
a component of many enzymes, is involved in the
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synthesis, storage and release of insulin [10]. Studies have
reported that Zn has been implicated in altered lipid
markers, insulin resistance, oxidative stress, inflammatory
markers [11, 12], adiposity and serum leptin level [13].
Furthermore, a recent review and meta-analysis reported
that zinc supplementation has favourable effects on
plasma lipid parameters and that it also significantly
reduces total cholesterol, low-density lipoprotein (LDL)
cholesterol and triglycerides [14]. A high prevalence of
coronary artery disease (hypertension, hypertriglyceridae-
mia and low high-density lipoprotein (HDL) cholesterol
levels), diabetes and glucose intolerance was reported in
populations consuming lower intakes of dietary zinc [15].
Although there is accumulating evidence on the relation-
ship between serum zinc and human metabolism, there is
a lack of evidence on Zn as a potential therapeutic agent
to reduce weight and improve metabolic parameters in
obese adults. Thus, this study aims to evaluate the effects
of Zn supplementation on weight reduction and metabolic
parameters in obese adults in Sri Lanka.
Methods/design
Study design
This is a randomized double-blind, placebo-controlled
clinical trial.
Setting
The proposed clinical trial will be held at the clinical
laboratory, Department of Applied Nutrition, Wayamba
University of Sri Lanka for 3 months to assess the
efficacy of daily zinc 20 mg supplementation in obese
subjects. Figure 1 illustrates the timeline of the study.
Participants (inclusion and exclusion criteria)
Subjects will be obese (BMI ≥25) individuals aged
between 18–60 years of both genders. Definitions for
anthropometric cut-offs for obesity were based on WHO
cut-offs for Asians [16]. The following exclusion criteria
will be applied: subjects on any other vitamin or mineral
supplementations or the current use of a weight loss
medicine or special dietary modification, history of
diabetes mellitus or any metabolic disease, alcohol
consumption >20 g/day, presently having acute diseases
or other untreated illness requiring treatment, impaired
hepatic or renal functions, lactation, pregnancy or
unwillingness to use an effective form of birth control
for women of child-bearing years and history or
presence of any condition, in the investigator’s opinion,
that would endanger the individual’s safety or affect the
study result. Furthermore, subjects will be suspended
from the study if they demand to discontinue it and/or
have low rates of compliance.
Randomization and blinding
After the screening phase, subjects will be stratified ac-
cording to age, gender and BMI and randomly assigned
to one of two groups of 40 subjects each into the test
and placebo. Assignment to either group will be per-
formed by a computer-generated 1:1 randomization.
The study treatments are double blinded to both
investigator and subject. The supplements and placebo
will be produced by Astron Lanka Limited, Ratmalana,
Sri Lanka. They will be responsible for the labelling and
packaging of the Zn capsule and placebo with code
numbers.
Interventions
The study will be conducted for 3 months. The visits
and the evaluations will be as follows: screening
(visit 0), baseline (visit 1) and 3 month (visit 2). The
treatment drug is a capsule containing elemental
zinc 20 mg as the active ingredient (as zinc
sulphate). The supplemented Zn dose was set based
on a previous study published in the literature [14].
The placebo capsule will contain lactose monohy-
drate. The placebo will be manufactured to have a
similar appearance, shape, weight, taste and colour
as the Zn capsule. The subjects will receive either
one capsule of Zn or an identical placebo daily,
taken after dinner for a period of 3 months. Figure 1
illustrates the schedule of the study.
Measurements
The primary endpoint is weight reduction among obese
adults. Body weight will be measured using a calibrated
electronic floor scale (SECA 815 by SECA GmbH & Co.
KG, Hamburg, Germany) to the nearest 0.1 kg. Height
will be measured to the nearest 0.1 cm using an upright
plastic portable stadiometer (IP0955, Invicta Plastics,
Leicester, UK). BMI will be calculated as weight (in
kilograms) divided by the square of height (in metres).
Waist circumference will be measured with a non-elastic
tape (SECA 203 by SECA GmbH & Co. KG, Hamburg,
Germany) at a point midway between the lower border
of the rib cage and the iliac crest at the end of normal
expiration. Similarly, the hip circumference also will be
measured at the widest part of the buttocks at the
intertrochanteric level to the nearest 0.1 cm. All
anthropometric measures will be taken by trained
research assistants using standard equipment according
to the standard guidelines [17]. In addition, glycaemic
status (fasting blood glucose), lipid parameters (total
cholesterol, triglyceride levels, HDL cholesterol, LDL
cholesterol) and blood pressure will be measured.
Glucose in the plasma will be determined by the glucose
oxidase/peroxidase (GOD-Perid) method using commer-
cially available kits (ProDia International, USA) and a
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chemistry analyser (Erba Chem-7, UK). Total
cholesterol, triglyceride levels and HDL cholesterol
(HDL-C) will be measured with enzymatic colorimetric
assays using commercially available kits (ProDia
International, USA) and an Erba Chem-7 chemistry
analyser (Erba Molecular, Cambridgeshire, UK). LDL
cholesterol (LDL C) will be estimated based on the
Friedewald equation [18]. Systolic (SBP) and diastolic
blood pressure (DBP) will be measured after at least a
10-min rest with Omron IA2 digital blood pressure
monitors (Omron Healthcare, Singapore).
Sample size
The minimum estimated sample size was 35 for each
study arm, and a 15 % dropout rate was calculated.
Finally, 40 subjects were recruited for each group.
Dietary assessment
A 7-day diet diary will be used to measure energy and nu-
trient intakes and they will be calculated using NutriSurvey
2007 (EBISpro, Germany) nutrient analysis software,
modified for Sri Lankan food items and recipes.
Fig. 1 Timeline of the study
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Compliance calculation
Subjects are asked to return any remaining drugs, and
their compliance will be evaluated by using the formula:
Compliance %ð Þ ¼ Distributed capsules‐remainining capsules
Distributed capsules
 100
Data protection and confidentiality
Confidentiality will be maintained by giving all
volunteers a unique identification code. Names will not
be used in any reports or publications. Data will be kept
for a maximum of 5 years. The files which match the
personal details of the participants with their individual
identification code will be held separately in a locked
filing cabinet within the Department of Applied Nutrition
and will be accessible only to the study investigators.
Statistical analysis
SPSS version 16 (SPSS Inc., Chicago, IL, USA) will be used
for data analysis. For categorical data, Pearson’s chi-
squared test will be used to verify the association in the
treatment and placebo groups. For binary and continuous
outcomes, logistic and linear regression models will be
used, respectively. Statistical analysis will be performed by
descriptive analysis, with numerical variables expressed as
the mean and standard deviation (SD) or median and
interquartile range. The Kolmogorov-Smirnov test will be
used to test the normality of the sample distribution. The
Student t test will be used in cases with a normal distribu-
tion to compare means between the two groups. The
Wilcoxon test will be used in cases with a non-normal
distribution. P values <0.05 will indicate a significant asso-
ciation in all of the statistical tests used.
Discussion
The level of obesity has reached epidemic proportions in
many countries. Several non-communicable diseases
such as diabetes, metabolic syndrome, ischaemic heart
diseases and certain cancers are strongly associated with
obesity. Obesity is a major health burden in south Asian
countries including Sri Lanka [3]. Only a very limited
number of clinical trials have been conducted in Sri
Lanka, although the country is experiencing several
health burdens [2, 4, 5]. Experiments on low-cost and
effective treatment methods for major health disease in
Sri Lanka are greatly needed.
In parallel to the problems of obesity and non-
communicable diseases (NCDs), south Asian countries
are facing malnutrition and micronutrient deficiencies. A
systematic review and meta-analysis showed satisfactory
effects of Zn supplementation on diabetes and other
metabolic markers, especially studies conducted in
developing countries [19]. Hashemipour et al. showed
significant body weight reduction and metabolic
improvement in a group of pre-pubertal obese children in
Iran [11]. However, there is a scarcity of published data on
zinc supplementation on obese adults from developing
countries where marginal deficiencies are possible.
The proposed study, as far as we are aware, will be the
only study of its type to be conducted in Sri Lanka and
one of the few studies conducted elsewhere in the world.
The findings will be of major importance to clinical
practice for the management of obesity using nutritional
supplements and to the general public, who will learn
about the health impact of taking Zn supplements to
lose weight and thus avoid some chronic diseases. The
results will also assess mineral deficiencies in people
who are obese and are at risk of developing obesity-
related diseases. Because of the fundamental nature of
the work proposed in this project, the findings are likely
to be of significance to a wide range of users such as
hospital health care teams and ministries of health who
conduct supplementation and fortification programmes
to improve the health status of the general public.
Strengths and weaknesses
The first advantage is that randomized, double-blind
placebo controlled trials represent the highest level of
research evidence. Second, there are no reported adverse
effects of a dose of 20 mg/d of zinc supplementation on
otherwise healthy adults. Previous studies on supple-
mentation with zinc (20 mg/d) did not show any adverse
effects [11]. We expect a high level of patient compli-
ance in this study. Third, the measurement of metabolic
parameters such as plasma lipids, glucose and blood
pressure along with anthropometric changes will provide
a complete picture of the effect of zinc supplementation
on obesity and associated risk factors. However, we do
not have the funding or the technical facilities to
measure serum zinc values, which may hinder the ability
to interpret results related to patients’ zinc status.
Trial status
This trial is in the recruitment stage.
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